Naive Like CAR T Product Cells Track Durable Lymphoma Benefit

Company Kite (Gilead) Event Type Peer-reviewed publication Modality Autologous CD19 CAR T cell therapy; product phenotype biomarker Asset Axicabtagene ciloleucel (axi-cel) Target CD19 Disease Area Non-Hodgkin lymphoma Summary A peer reviewed multicenter analysis of axicabtagene ciloleucel products from 580 patients with non-Hodgkin lymphoma links a…